|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
02.07.26 - 10:48
|
European Champions: ASML, Novo und GSK sorgen für Schwung (Der Aktionaer)
|
|
|
In einer volatilen Börsenphase hat sich der European Champions Index sehr robust entwickelt und steht nun kurz vor einem neuen Allzeithoch. Wesentliche Erfolgsfaktoren sind die defensive Aufstellung und die Branchenstreuung. Mit Novo Nordisk, Novartis, Astrazeneca, GSK, Roche und Sanofi entfällt rund die Hälfte der Aktien auf den Gesundheitssektor....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
01.07.26 - 15:21
|
The European Investment Bank Grants Orano a Loan of €125 Million to Finance Orano Med′s Innovations and Industrial Infrastructure (Business Wire)
|
|
|
PARIS--(BUSINESS WIRE)--The European Investment Bank (EIB) and Orano announced today the signing of a €125 million credit line to finance the development of Orano Med and its industrial infrastructure, notably the construction of the Advanced Thorium Extraction Facility (ATEF), located in Bessines-sur-Gartempe, France.Orano Med, a subsidiary of the Orano group specializing in nuclear medicine, develops lead-212-based targeted alpha therapies, a new class of cancer treatments. By using the unique properties of alpha-emitter lead-212, these therapies aim at the targeted destruction of cancer cells, while limiting the impact on surrounding healthy tissue. Orano Med's clinical pipeline currently comprises four programs, run either independently or with its partners, evaluating these treatments across a wide range of cancer types that represent significant unmet medical needs. The company's partners include major pharmaceutical groups such as Sanofi and Roche, as well as Swiss biotech Molecular Partners.AT...
|
|
|
|
|
|
|
30.06.26 - 09:42
|
Roche Neutral (DPA-AFX)
|
|
|
NEW YORK (dpa-AFX Analyser) - Die US-Investmentbank Goldman Sachs hat das Kursziel für Roche von 346 auf 348 Franken angehoben, aber die Einstufung auf "Neutral" belassen. Analyst James Quigley rechnet mit einem unschönen Halbjahresbericht der Schweizer, ......
|
|
|
|
|
|
|
30.06.26 - 07:15
|
FDA Grants Priority Review To Genentech′s Application for Enspryng, the First and Only At-Home Subcutaneous Treatment Option for Thyroid Eye Disease (TED) (Business Wire)
|
|
|
The filing application is based on improvements seen across key efficacy endpoints from the global Phase III SatraGO-1 and SatraGO-2 studies, including proptosis (bulging eyes) and diplopia (double vision) in active TED
Enspryng (satralizumab) has the potential to become the first at-home subcutaneous disease-modifying standard of care for TED
TED is an autoimmune disease affecting approximately 155 out of every 100,000 people that can lead to facial disfigurement and vision-threatening complications if left untreated
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has accepted and granted priority review to a supplemental Biologics License Application (sBLA) for Enspryng® (satralizumab) for the treatment of thyroid eye disease (TED). The filing acceptance is based on results from the two randomized, placebo-controlled global Phase III SatraGO studies assessing the safety an...
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
